VCA
BIO icon

Verdence Capital Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Verdence Capital Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-631
Closed -$210K – 325
2019
Q3 		$210K Buy
+631
New +$206K 0.06% 277

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Verdence Capital Advisors's BIO Position: Q4 2019 in Review

Verdence Capital Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2019, closing a stake of 631 shares — an estimated $210K sold.

Verdence Capital Advisors first reported a position in BIO in Q3 2019 and held it in 1 quarter. The position peaked at $210K in Q3 2019. 386 funds tracked by Wall St. Rank hold BIO as of Q4 2019.

  • Verdence Capital Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q4 2019 after selling out during the quarter.
  • Verdence Capital Advisors sold 631 Bio-Rad Laboratories Class A shares in Q4 2019, an estimated $210K.
  • Verdence Capital Advisors first reported a position in Bio-Rad Laboratories Class A in Q3 2019 and held it in 1 quarter.
  • Verdence Capital Advisors's Bio-Rad Laboratories Class A position peaked at $210K in Q3 2019.
  • 386 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2019.

Based on Verdence Capital Advisors's 13F filing for Q4 2019, filed 3 Feb 2020.